Nature medicine · 2025
Data-driven subtypes of polycystic ovary syndrome and their association with clinical outcomes.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gao Xueying, Zhao Shigang, Du Yanzhi, Yang Ziyi, Tian Ye, Zhao Junli, Yuan Xi, Santos Betania R, Wei Daimin, Cui Linlin, Yan Junhao, Qin Yingying, Shi Yuhua, Tang Rong, Sun Yun, Hu Jingmei, Ding Lingling, Song Xueru, Ha Lingxia, Li Jingyu, China Women’s Reproductive Metabolic Network, Zhang Heping, Spritzer Poli Mara, Yildiz Bulent O, Stener-Victorin Elisabet, Yong Eu-Leong, Ou Xiang-Hong, Legro Richard S, Zhao Han, Chen Zi-Jiang
Аннотация
Polycystic ovary syndrome (PCOS) is a common and heterogeneous endocrine disorder that affects 11%-13% of women worldwide, with profound implications for fertility and long-term metabolic health. Here we identify four reproducible subtypes-PCOS with hyperandrogen, with obesity, with high-sex hormone-binding globulin and with high-luteinizing hormone-anti-Müllerian hormone-through unsupervised clustering of 9 clinical variables in 11,908 affected women, validated across 5 international cohorts. Prospective 6.5-year follow-up and in vitro fertilization treatment data revealed distinct reproductive and metabolic trajectories: hyperandrogenic PCOS showed the highest risk of second trimester pregnancy loss and dyslipidemia incidence; PCOS with obesity exhibited the most severe metabolic complications, lowest live birth rates and highest PCOS remission rate; PCOS with high-sex hormone-binding globulin demonstrated favorable reproductive outcomes and the lowest incidence of diabetes and hypertension; and PCOS with high-luteinizing hormone-anti-Müllerian hormone had the greatest risk of ovarian hyperstimulation and the lowest PCOS remission rate. These findings advance understanding of PCOS heterogeneity and provide a framework for subtype-based risk stratification and personalized management.